GlassScriptPhysician profile
Shazia Billal
NPI 1144270448
$14,568.87
in general payments reported to CMS, 2019-2025
69 companies · $1,032 in 2025
The $1,032 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,895 · 2020: $2,371 · 2021: $3,963 · 2022: $1,815 · 2023: $1,632 · 2024: $1,860 · 2025: $1,032.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,440 · Education: $84.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,439.64 |
| Education | $84.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,862.40 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Biohaven Pharmaceuticals, INC. | $1,218.62 | 2021 | |
| Novo Nordisk INC | $1,149.71 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $1,140.23 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $975.70 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $914.46 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Otsuka America Pharmaceutical, INC. | $639.33 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Amgen INC. | $541.37 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $489.42 | 2019-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $421.86 | 2021-2023 | |
| Pfizer INC. | $364.58 | 2019-2025 | |
| Allergan, INC. | $349.03 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.06 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $257.06 | 2019-2022 | |
| Astellas Pharma US INC | $252.68 | 2019-2024 | Veozah |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shazia Billal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.